Molecular basis of thrombolytic therapy

Journal of Nuclear Cardiology

Volumn 7, Issue 4, 2000, Pages 373-381

  Lijnen, H R ^a   Collen, D ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ANTIPLASMIN; ALTEPLASE; ANISTREPLASE; ASPAC; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; FIBRIN; FIBRINOGEN; HEPARIN; LANOTEPLASE; MACROGOL DERIVATIVE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROUROKINASE; RECOMBINANT ENZYME; RECOMBINANT STAPHYLOKINASE; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ACUTE HEART INFARCTION; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CORONARY ARTERY RECANALIZATION; DRUG CONFORMATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; PRIORITY JOURNAL; RECANALIZATION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; THROMBOEMBOLISM;

EID: 0033841795     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1067/mnc.2000.108608     Document Type: Article

References (49)

1. Basic and clinical aspects of fibrinolysis and thrombolysis
2. Fibrin-selective thrombolytic therapy for acute myocardial infarction
3. Trials comparing the available thrombolytic agents
4. Meta-analysis of all available published clinical trials (1958-1990) on thrombolytic therapy for AMI: Relative efficacy of different therapeutic strategies
5. Molecular cloning and characterization of a full-length cDNA clone for human plasminogen
6. On the regulation and control of fibrinolysis
7. Cloning and expression of human tissue-type plasminogen activator cDNA in E coli
8. Strategies for the improvement of thrombolytic agents
9. Cloning and expression of the gene for pro-urokinase in Escherichia coli
10. Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor
11. 2-plasmin inhibitor in human plasma
12. Studies on a form of alpha 2-antiplasmin in plasma which does not interact with the lysine-binding sites in plasminogen
13. 2-plasmin inhibitor to fibrin
14. Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family
15. Purification and characterization of a plasminogen activator inhibitor-1-binding protein from human plasma. Identification as a multimeric form of S protein
16. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants
17. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a non-inhibitory substrate for tissue-type plasminogen activator
18. 2-antiplasmin and plasmin
19. On the kinetics of the reaction between human antiplasmin and plasmin
20. Plasminogen activator inhibitors-a review
21. Kinetics of inhibition of activator by plasminogen-activator tissue-type and urokinase-type plasminogen inhibitor type 1 and type 2
22. Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second site' interactions
23. Serpin-resistant mutants of human tissue-type plasminogen activator
24. A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor
25. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin
26. The mechanism of plasminogen activation and the variability of the fibrin effector during tissue-type plasminogen activator-mediated fibrinolysis
27. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
28. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma
29. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis
30. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?
31. Staphylokinase, a fibrin-specific bacterial plasminogen activator
32. Staphylokinase: A potent, uniquely fibrin-selective thrombolytic agent
33. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species
34. 158 → Glu)
35. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities
36. A transitional state of pro-urokinase that has a higher catalytic efficiency against Glu-plasminogen than urokinase
37. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK
38. A study of the activation of fibrin-bound plasminogen by tissue-type plasminogen activator, single chain urokinase and sequential combinations of the activators
39. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis
40. Role of α2-antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma
41. Complete amino acid sequence of streptokinase and its homology with serine proteases
42. Mechanism of activation of human plasminogen by streptokinase
43. Interaction of streptokinase with plasminogen. Isolation and characterization of a streptokinase degradation product
44. Fibrinolysis with acyl-enzymes: A new approach to thrombolytic therapy
45. Tissue-type plasminogen activator
46. The GUSTO-III investigators. A comparison of reteplase with alteplase for acute myocardial infarction
47. TNK-tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial
48. TNK-tissue plasminogen activator compared with front-loaded tissue plasminogen activator in acute myocardial infarction: Primary results of the TIMI-10B trial
49. The plasminogen (fibrinolytic) system